|
|
|
Corporate Profile: Kolltan Pharmaceuticals
| Summary: |
| Kolltan Pharmaceuticals is focused on the development of monoclonal antibody and small-molecule drugs targeting receptor tyrosine kinases. |
| Address (HQ): |
300 George Street
Suite 530
New Haven, CT 06511 |
| Phone #'s (HQ): |
| Main |
(203) 773-3000 |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| Fax #'s (HQ): |
| Main |
(203) 773-1300 |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| Financial
information: |
| not known |
| Number
of employees: |
| not known |
| Issued United States patents: |
| Issued U.S. patents: 1976-present: patent link. |
| Filed United States patent applications: |
| Filed U.S. patent applications: 2001-present: patent
link. |
| Publications on PubMed: |
| Scientific publications on PubMed with an author from the company: publications
link. |
|
|
|
